Brief Communication

Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer

Authors: Xing-mei Liang1,2, Qiong Qin1,2, Bo-ning Liu1, Xiao-qing Li1,3, Li-li Zeng1,2, Jing Wang1, Ling-ping Kong1,2, Dian-sheng Zhong1,2, Lin-lin Sun1
1 Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China
2 Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China
3 Phase I Clinical Trial Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Correspondence to: Dian-sheng Zhong: dzhong@tmu.edu.cn, Lin-lin Sun: lsun1@tmu.edu.cn,
DOI: 10.1038/s41401-020-00577-1
Received: 17 July 2020
Accepted: 8 November 2020
Advance online: 7 January 2021

Abstract

The third-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), represented by osimertinib, has achieved remarkable clinical outcomes in the treatment of non-small-cell lung cancer (NSCLC) with EGFR mutation. However, resistance eventually emerges in most patients and the underlying molecular mechanisms remain to be fully understood. In this study, we generated an osimertinib-acquired resistant lung cancer model from a NSCLC cell line H1975 harboring EGFR L858R and T790M mutations. We found that the capacity of DNA damage repair was compromised in the osimertinib resistant cells, evidenced by increased levels of γH2AX and higher intensity of the comet tail after withdrawal from cisplatin. Pharmacological inhibiting the activity or genetic knockdown the expression of DNA-PK, a key kinase in DNA damage response (DDR), sensitized the resistant cells to osimertinib. Combination of osimertinib with the DNA-PK inhibitor, PI-103, or NU7441, synergistically suppressed the proliferation of the resistant cells. Mechanistically, we revealed that DNA-PK inhibitor in combination with osimertinib resulted in prolonged DNA damage and cell cycle arrest. These findings shed new light on the mechanisms of osimertinib resistance in the aspect of DNA repair, and provide a rationale for targeting DNA-PK as a therapeutic strategy to overcome osimertinib-acquired resistance in NSCLC.
Keywords: NSCLC; EGFR-TKI resistance; osimertinib; DNA damage repair; DNA-PK

Article Options

Download Citation

Cited times in Scopus